Livogrit Prevents Methionine-Cystine Deficiency Induced Nonalcoholic Steatohepatitis by Modulation of Steatosis and Oxidative Stress in Human Hepatocyte-Derived Spheroid and in Primary Rat Hepatocytes

References

• Dufour J-F, Scherer R, Balp -M-M, et al. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–A targeted literature review. Endocr Metab Sci. 2021;3: 100089.
   Google Scholar
• Kopec KL, Burns D. Nonalcoholic fatty liver disease. Nutr Clin Pract. 2011;26(5):565–576.
   PubMed Web of Science ®Google Scholar
• Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Clin Pract Gastroenterol Hepatol. 2021;18(4):223–238.
   Google Scholar
• Fraile JM, Palliyil S, Barelle C, et al. Non-Alcoholic Steatohepatitis (NASH) - A review of a crowded clinical landscape, driven by a complex disease. Drug Des Devel Ther. 2021;15:3997–4009.
   PubMed Web of Science ®Google Scholar
• Albhaisi Somaya A.M., Sanyal Arun J. New drugs for NASH. Liver Int. 2021;41(S1):112–118.
   PubMed Web of Science ®Google Scholar
• Boeckmans J, Natale A, Buyl K, et al. Human-based systems: mechanistic NASH modelling just around the corner? Pharmacol Res. 2018;134:257–267.
   PubMed Web of Science ®Google Scholar
• Shah U-K, Mallia JDO, Singh N, et al. A three-dimensional in vitro HepG2 cells liver spheroid model for genotoxicity studies. Mutat Res Genet Toxicol Environ Mutagen. 2018;825:51–58.
   PubMed Web of Science ®Google Scholar
• Ware MJ, Colbert K, Keshishian V, et al. Generation of homogenous three-dimensional pancreatic cancer cell spheroids using an improved hanging drop technique. Tissue Eng Part C Methods. 2016;22(4):312–321.
   PubMed Web of Science ®Google Scholar
• Yin J, Ren W, Yang G, et al. l-Cysteine metabolism and its nutritional implications. Mol Nutr Food Res. 2016;60(1):134–146.
   PubMed Web of Science ®Google Scholar
• Cho I-J, Kim D, Kim E-O, et al. Cystine and methionine deficiency promotes ferroptosis by inducing B-cell translocation Gene 1. Antioxidants. 2021;10(10):1543.
   Web of Science ®Google Scholar
• Rehman T, Shabbir MA, Inam-Ur-Raheem M, et al. Cysteine and homocysteine as biomarker of various diseases. Food Sci Nutr. 2020;8(9):4696–4707.
   PubMed Web of Science ®Google Scholar
• Santos JCF, de Araújo ORP, Valentim IB, et al. Choline and cystine deficient diets in animal models with hepatocellular injury: evaluation of oxidative stress and expression of RAGE, TNF-α, and IL-1β. Oxid Med Cell Longev. 2015;2015:121925.
   PubMed Web of Science ®Google Scholar
• Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci. 2016;17(9):1575.
   PubMed Web of Science ®Google Scholar
• Balkrishna A, Sakat SS, Ranjan R, et al. Polyherbal medicine divya sarva-kalp-kwath ameliorates persistent carbon tetrachloride induced biochemical and pathological liver impairments in Wistar rats and in HepG2 cells. Front Pharmacol. 2020;11:288.
   PubMed Web of Science ®Google Scholar
• Balkrishna A, Gohel V, Singh R, et al. Tri-herbal medicine Divya Sarva-Kalp-Kwath (Livogrit) regulates fatty acid-induced steatosis in human HepG2 cells through inhibition of intracellular triglycerides and extracellular glycerol levels. Molecules. 2020;25(20):4849.
   PubMed Web of Science ®Google Scholar
• Balkrishna A, Gohel V, Singh R, et al. Livogrit ameliorates acetaldehyde-induced steatosis in HepG2 cells through modulation of lipogenesis and β-oxidation pathways. Phytomed Plus. 2021;1(3):100067
   Google Scholar
• Lasli S, Kim H-J, Lee K, et al. A human liver-on-a-chip platform for modeling nonalcoholic fatty liver disease. Adv Biosyst. 2019;3(8):1900104.
   PubMed Web of Science ®Google Scholar
• Bril F, Kalavalapalli S, Clark VC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558–566.e2.
   PubMed Web of Science ®Google Scholar
• Boeckmans J, Natale A, Rombaut M, et al. Anti-NASH drug development hitches a lift on PPAR agonism. Cells. 2020;9(1):37.
   Web of Science ®Google Scholar
• Au -Shen L, Au -Hillebrand A, Au - Wang DQH, et al. Isolation and primary culture of rat hepatic cells. JoVE. 2012;64:e3917.
   Google Scholar
• Wang L, Stegemann JP. Extraction of high quality RNA from polysaccharide matrices using cetyltrimethylammonium bromide. Biomaterials. 2010;31(7):1612–1618.
   PubMed Web of Science ®Google Scholar
• Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem. 1976;74(1):214–226.
   PubMed Web of Science ®Google Scholar
• Zanoni M, Piccinini F, Arienti C, et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016;6(1):19103.
   PubMed Web of Science ®Google Scholar
• Gaskell H, Sharma P, Colley HE, et al. Characterization of a functional C3A liver spheroid model. Toxicol Res (Camb). 2016;5(4):1053–1065.
   PubMed Web of Science ®Google Scholar
• Cavo M, Delle Cave D, D’Amone E, et al. A synergic approach to enhance long-term culture and manipulation of MiaPaCa-2 pancreatic cancer spheroids. Sci Rep. 2020;10(1):10192.
   PubMed Web of Science ®Google Scholar
• Takaki A, Uchida D, Yamamoto K. Chapter 12 - Redox Signaling in NASH. In: Muriel P, editor. Liver Pathophysiology. Boston: Academic Press; 2017. p. 169–180.
   Google Scholar
• Esani MA. The physiological sources of, clinical significance of, and laboratory-testing methods for determining enzyme levels. Lab Med. 2014;45(1):e16–e18.
   Web of Science ®Google Scholar
• Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014;349(sep19 15):g4596–g4596.
   PubMed Web of Science ®Google Scholar
• Xu Y, Guo W, Zhang C, et al. Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mechanism, and clinical application. Front Pharmacol. 2020;11:601.
   PubMed Web of Science ®Google Scholar
• Li S, Xu Y, Guo W, et al. The impacts of herbal medicines and natural products on regulating the hepatic lipid metabolism. Front Pharmacol. 2020;11:351.
   PubMed Web of Science ®Google Scholar
• Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654–667.
   PubMed Web of Science ®Google Scholar
• Stone KP, Ghosh S, Kovalik JP, et al. The acute transcriptional responses to dietary methionine restriction are triggered by inhibition of ternary complex formation and linked to Erk1/2, mTOR, and ATF4. Sci Rep. 2021;11(1):3765.
   PubMed Web of Science ®Google Scholar
• Aguilar-Olivos NE, Carrillo-Córdova D, Oria-Hernández J, et al. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Ann Hepatol. 2015;14(4):487–493.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhang H, Luan Z, et al. Farnesoid X receptor (FXR) activation induces the antioxidant protein metallothionein 1 expression in mouse liver. Exp Cell Res. 2020;390(1):111949.
   PubMed Web of Science ®Google Scholar
• Cyphert HA, Ge X, Kohan AB, et al. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem. 2012;287(30):25123–25138.
   PubMed Web of Science ®Google Scholar
• Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr. 2011;53(2):131–140.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kwon DY, Kwak JH, et al. Tunicamycin-induced er stress is accompanied with oxidative stress via abrogation of sulfur amino acids metabolism in the liver. Int J Mol Sci. 2018;19(12):12.
   Web of Science ®Google Scholar
• Boeckmans J, Natale A, Rombaut M, et al. Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. Cell Biol Toxicol. 2021;37(2):293–311.
   PubMed Web of Science ®Google Scholar
• Reddy YPK, Uppalapati Suraj. Assessment of glutathione level in non-alcoholic fatty liver disease patients. Acad J Med. 2020;3(1):19–22.
   Google Scholar
• Papac-Milicevic N, Busch CJL, Binder CJ. Malondialdehyde epitopes as targets of immunity and the implications for atherosclerosis. Adv Immunol. 2016;131:1–59.
   PubMed Web of Science ®Google Scholar
• Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss-Isakov N, et al. Serum malondialdehyde is associated with non-alcoholic fatty liver and related liver damage differentially in men and women. Antioxidants. 2020;9(7):578.
   Web of Science ®Google Scholar
• Mutoh A, Ueda S. Peroxidized unsaturated fatty acids stimulate Toll-like receptor 4 signaling in endothelial cells. Life Sci. 2013;92(20):984–992.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Ruiz MC, Quiroz SC, Souza V, et al. Cytokines, growth factors, and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde, and LPS. Toxicology. 1999;134(2):197–207.
   PubMed Web of Science ®Google Scholar
• Han L-P, Sun B, Li C-J, et al. Effect of celastrol on toll-like receptor 4-mediated inflammatory response in free fatty acid-induced HepG2 cells. Int J Mol Med. 2018;42:2053–2061.
   PubMed Web of Science ®Google Scholar
• Sharifnia T, Antoun J, Verriere TGC, et al. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309(4):G270–G278.
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Ramana KV. Regulation of NF-κB-induced inflammatory signaling by lipid peroxidation-derived aldehydes. Oxid Med Cell Longev. 2013;2013:690545.
   PubMed Web of Science ®Google Scholar
• Krishnasamy Y, Gooz M, Li L, et al. Role of mitochondrial depolarization and disrupted mitochondrial homeostasis in non-alcoholic steatohepatitis and fibrosis in mice. Int J Physiol Pathophysiol Pharmacol. 2019;11(5):190–204.
   PubMedGoogle Scholar
• Begriche K, Massart J, Robin M-A, et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58(4):1497–1507.
   PubMed Web of Science ®Google Scholar
• Simões ICM, Fontes A, Pinton P, et al. Mitochondria in non-alcoholic fatty liver disease. Int J Biochem Cell Biol. 2018;95:93–99.
   PubMed Web of Science ®Google Scholar
• Peng K-Y, Watt MJ, Rensen S, et al. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression. J Lipid Res. 2018;59(10):1977–1986.
   PubMed Web of Science ®Google Scholar
• Léveillé M, Estall JL. Mitochondrial dysfunction in the transition from NASH to HCC. Metabolites. 2019;9(10):233.
   PubMed Web of Science ®Google Scholar
• Smati S, Canivet CM, Boursier J, et al. Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert Opin Investig Drugs. 2021;30(8):813–825.
   PubMed Web of Science ®Google Scholar
• Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 2018;9:6.
   PubMed Web of Science ®Google Scholar
• Kozyra M, Johansson I, Nordling Å, et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Sci Rep. 2018;8(1):14297.
   PubMed Web of Science ®Google Scholar
• Leung BM, Lesher-Perez SC, Matsuoka T, et al. Media additives to promote spheroid circularity and compactness in hanging drop platform. Biomater Sci. 2015;3(2):336–344.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang L, Sun Y, et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR γ agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers. 2006;10(3):349–360.
   PubMed Web of Science ®Google Scholar
• Jain SK, Tripathi KS, Parihar GV, et al. Protective effect of extract of Boerhaavia diffusa and Silybum marianum in combination against fructose induced non alcoholic fatty liver in rats. Int J Green Pharm. 2013;7(3):230–235
   Google Scholar
• Al Zarzour RH, Ahmad M, Asmawi MZ, et al. Phyllanthus Niruri standardized extract alleviates the progression of non-alcoholic fatty liver disease and decreases atherosclerotic risk in Sprague–Dawley rats. Nutrients. 2017;9(7):766.
   PubMed Web of Science ®Google Scholar
• Tai C-J, Choong C-Y, Shi Y-C, et al. Solanum nigrum protects against hepatic fibrosis via suppression of hyperglycemia in high-fat/ethanol diet-induced rats. Molecules. 2016;21(3):269.
   PubMed Web of Science ®Google Scholar
• Chao J, Cheng H-Y, Chang M-L, et al. Gallic acid ameliorated impaired lipid homeostasis in a mouse model of high-fat diet—and streptozotocin-induced NAFLD and diabetes through Improvement of β-oxidation and Ketogenesis. Front Pharmacol. 2021;11:2469.
   Web of Science ®Google Scholar
• Wu N, Zu Y, Fu Y, et al. Antioxidant activities and xanthine oxidase inhibitory effects of extracts and main polyphenolic compounds obtained from geranium sibiricum L. J Agric Food Chem. 2010;58(8):4737–4743.
   PubMed Web of Science ®Google Scholar
• Zhang R, Chu K, Zhao N, et al. Corilagin alleviates nonalcoholic fatty liver disease in high-fat diet-induced C57BL/6 mice by ameliorating oxidative stress and restoring autophagic flux. Front Pharmacol. 1693;2020:10.
   Google Scholar
• Hong T, Chen Y, Li X, et al. The role and mechanism of oxidative stress and nuclear receptors in the development of NAFLD. Oxid Med Cell Longev. 2021;2021:6889533.
   PubMed Web of Science ®Google Scholar
• Kushwaha PP, Kumar R, Neog PR, et al. Characterization of phytochemicals and validation of antioxidant and anticancer activity in some Indian polyherbal ayurvedic products. Vegetos. 2021;34(2):286–299.
   Google Scholar
• Aziza SA, Azab Mel S, El-Shall SK. Ameliorating role of rutin on oxidative stress induced by iron overload in hepatic tissue of rats. Pak J Biol Sci. 2014;17(8):964–977.
   PubMedGoogle Scholar
• Dasarathy S, Yang Y, McCullough AJ, et al. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23(5):382–388.
   PubMed Web of Science ®Google Scholar
• Erickson A, Moreau R. The regulation of FGF21 gene expression by metabolic factors and nutrients. Horm Mol Biol Clin Investig. 2017;30:1.
   Web of Science ®Google Scholar
• Boeckmans J, Buyl K, Natale A, et al. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. Pharmacol Res. 2019;144:377–389.
   PubMed Web of Science ®Google Scholar
• Irie M, Sohda T, Anan A, et al. Reduced glutathione suppresses oxidative stress in nonalcoholic fatty liver disease. Euroasian J Hepatogastroenterol. 2016;6(1):13–18.
   PubMedGoogle Scholar
• Tesseraud S, Métayer Coustard S, Collin A, et al. Role of sulfur amino acids in controlling nutrient metabolism and cell functions: implications for nutrition. Br J Nutr. 2008;101(8):1132–1139.
   PubMed Web of Science ®Google Scholar
• Salomone F, Godos J, Zelber-Sagi S. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. Liver Int. 2016;36(1):5–20.
   PubMed Web of Science ®Google Scholar
• Tsai T-H, Yu C-H, Chang Y-P, et al. Protective effect of caffeic acid derivatives on tert-butyl hydroperoxide-induced oxidative hepato-toxicity and mitochondrial dysfunction in HepG2 cells. Molecules. 2017;22(5):702.
   PubMed Web of Science ®Google Scholar
• Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf. 2010;9(2):347–354.
   PubMed Web of Science ®Google Scholar